Can you reverse artery plaque? What repeat scans show
- Sean Hashmi
- 18 minutes ago
- 4 min read
The short answer
Nothing you swallow dissolves plaque, because plaque sits inside the artery wall rather than in the channel your blood flows through. Plaque does shrink on repeat scans, but only a little: across 51 imaging trials in about 9,000 adults, the share of the vessel taken up by plaque fell by roughly one percentage point. Size is the wrong number to watch. The thin fibrous cap over the plaque is what decides whether you have a heart attack, sustained lipid lowering thickens that cap, and that is also why a coronary calcium score can climb fastest in the people whose plaque is shrinking.
What we cover
● Where plaque actually sits, and why no solvent, infusion, or capsule can reach it
● What percent atheroma volume measures, and how much it really moved across 51 imaging studies (Am J Prev Cardiol, 2024)
● Why the fibrous cap, not the size of the plaque, decides whether you have an event
● How much the cap thickened in patients treated hard in the year after a heart attack (JAMA, 2022)
● Why coronary calcium rose fastest in the group whose plaque was shrinking (J Am Coll Cardiol, 2015)
● What deep, sustained LDL lowering did to plaque in the strongest imaging trial we have (JAMA, 2016)
● What five years of an intensive lifestyle program did to coronary narrowing in 48 people, and that trial's real limits (JAMA, 1998)
● What 40 weekly EDTA chelation infusions did to blood lead, and what they did to heart attacks and strokes (JAMA, 2024)
Timestamps
00:00 Nothing dissolves plaque
00:17 Plaque does still shrink, a little
00:36 Meet Dr. Hashmi
00:52 The whole video in one sentence
01:01 The plaque that actually kills you
01:17 Why nothing dissolves plaque
01:47 What the "one point" number really means
02:34 The point change is the receipt, not the prize
02:58 The fibrous cap, explained
03:31 The cap study: 300 heart attack patients
03:53 The cap thickened nearly twice as much
04:24 What this means for your next scan
04:42 The calcium paradox
05:16 Calcium isn't the disease getting worse
05:53 What actually thickens the lid
06:05 The strongest test: LDL down to 37
06:33 Lower and longer: the entire mechanism
06:52 The drug-free path: 48 people, no medication
07:14 Five years later: shrinking vs. growing
07:52 Blood pressure, food pattern, and movement
08:54 What doesn't work: IV chelation and enzymes
10:03 A safety note on blood-thinning supplements
10:36 Your one action this week
11:19 Four reasons to call your doctor now
References
Rivera FB, et al. Am J Prev Cardiol. 2024;18:100645. PMID 38550634
Across 51 imaging trials, the share of the vessel taken up by plaque fell by about one percentage point and lipid-lowering therapy increased fibrous cap thickness; no systemic enzyme supplement appears anywhere in these trials, which makes them untested rather than disproven.
Evidence type: randomized trial, pooled across 51 imaging studies.
Nicholls SJ, et al. GLAGOV. JAMA. 2016;316(22):2373-84. PMID 27846344
Adding an injectable lipid-lowering drug to a statin brought LDL to 36.6 mg/dL and shrank plaque share by 0.95 percentage points against a 0.05 point gain on placebo, with 64.3 percent of treated patients regressing compared with 47.3 percent on placebo.
Evidence type: randomized trial.
Puri R, et al. J Am Coll Cardiol. 2015;65(13):1273-82. PMID 25835438
In a pooled analysis of eight imaging trials, coronary calcium increased in every group and increased fastest in the patients on the most intensive lipid-lowering treatment, the same patients whose plaque volume was falling.
Evidence type: randomized trial, pooled analysis of eight trials.
Raber L, et al. PACMAN-AMI. JAMA. 2022;327(18):1771-81. PMID 35368058
In 300 patients imaged again a year after a heart attack, the fibrous cap thickened by 62.67 micrometers on the more aggressive regimen against 33.19 micrometers on the comparator.
Evidence type: randomized trial.
Lamas GA, et al. TACT2. JAMA. 2024;332(10):794-803. PMID 39141382
In nearly 1,000 adults with diabetes and a prior heart attack, 40 weekly EDTA chelation infusions cut blood lead by more than half and produced no significant difference in heart attacks, strokes, or deaths.
Evidence type: randomized trial.
Ornish D, et al. JAMA. 1998;280(23):2001-7. PMID 9863851
In 48 people with coronary disease and no cholesterol medication, five years of an intensive lifestyle program lowered percent diameter stenosis by 3.1 points while usual care rose 11.8 points, and the usual-care group had more than twice the rate of cardiac events.
Evidence type: randomized trial, small sample and a demanding program.
GBD 2023 ischemic heart disease attribution. JAMA Cardiol. 2026. PMID 42455550
High blood pressure carries the largest single attributable share of deaths from ischemic heart disease.
Evidence type: observational.
Get the research behind videos like this in plain English every week, along with my free metabolic health guide, at guides.selfprinciple.org/metabolic.
This content is for educational purposes only and is not medical advice. Always consult your healthcare provider for individual care. The views expressed are Dr. Hashmi's own and do not represent his employer.
Never start, stop, or change the dose of any prescription medication without consulting your physician.
Comments